Published Paper Details:

Abstract Background: Bronchial asthma is a chronic, immune-mediated respiratory disorder marked by Th2-driven inflammation and airway hyperresponsiveness. Despite widespread use of inhaled corticosteroids (ICS) and bronchodilators, concerns remain about long-term safety and immunological gaps in asthma control. This systematic review evaluates the clinical and immunological evidence of individualised homeopathy in asthma, integrates safety/regulatory concerns, and proposes a framework for future research within an integrative medicine context. Methods: Databases including PubMed, Scopus, Web of Science, Cochrane Library, and AYUSH portals were searched for studies between 1980 and 2023 using terms like "homeopathy AND asthma" and "homeopathy AND eosinophils". Inclusion criteria: human studies assessing individualised homeopathy in asthma with clinical/immunological endpoints. Data extraction included trial design, sample size, remedy, asthma control, lung function, drug use, and biomarkers. Results: Of 58 screened studies, 17 met inclusion: 6 RCTs, 4 observational, 3 systematic reviews, and 4 pilot/immunological studies. Common remedies: Arsenicum album, Nux vomica, Sulphur, Pulsatilla, Silicea. Five studies reported reductions in eosinophils, IgE, or cytokines (e.g., IL-13). Observational data (>2000 patients) suggested improved symptom control and reduced medication dependency. However, methodological limitations included poor blinding, small samples, and non-standardised immune markers. Conclusion: Preliminary findings support individualised homeopathy as a complementary asthma therapy. However, current evidence is inconclusive due to weak methodology. Homeopathy should be used under professional supervision alongside conventional treatment. Future research must employ stratified designs, biomarker profiling, and transdisciplinary collaboration.